Eckert & Ziegler SE (FRA: EUZ)

Market Cap	1.10B
Revenue (ttm)	277.72M
Net Income (ttm)	29.39M
Shares Out	n/a
EPS (ttm)	1.40
PE Ratio	37.38
Forward PE	n/a
Dividend	5.15 (10.24%)
Ex-Dividend Date	Oct 3, 2024

Volume	1,185
Average Volume	360
Open	52.20
Previous Close	53.15
Day's Range	51.85 - 53.80
52-Week Range	32.50 - 53.80
Beta	n/a
RSI	71.82
Earnings Date	Mar 27, 2025

About Eckert & Ziegler SE

Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; ophthalmological products; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynt...

• Industry: Industrial Inorganic Chemicals
• Founded: 2024
• Employees: 1,075
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EUZ

Financial Performance

In 2023, Eckert & Ziegler SE's revenue was 246.09 million, an increase of 10.74% compared to the previous year's 222.23 million. Earnings were 26.30 million, a decrease of -10.17%.